Urinary Tract Infection Therapeutics Market | Growth, Trends, and Forecast (2019-2024)

Market Snapshot

Urinary Tract Infection Therapeutics Market_Image 1

Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

3.5%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Global Urinary Tract Infection Therapeutics market is expected to witness a CAGR of 3.5% during the forecast period. Certain factors that are driving the market growth include increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

According to the World Health Organization (WHO), in 1980, around 108 million people had diabetes, and this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7% in 1980 to 8.5% in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue in the forecast period. Therefore, with the increasing prevalence of diabetes, the number of cases of urinary tract infection (UTI) increases, and with an increase in UTI, the demand for drugs increases, driving the global urinary tract infection therapeutics market. Also, the launch of combination drugs, which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection therapeutics market.

However, according to the Center for Education & Research on Therapeutics, over 2 million cases of Adverse Drug Reactions (ADRs) are reported every year, out of which, there are approximately 100,000 deaths. According to FDA, it is estimated that each year over 350,000 ADRs occurs in the United States’ nursing homes alone. With such increasing cases of ADRs being reported in every corner of the globe, there is an awareness among the population for the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market. Additionally, the lack of awareness about the prevalence of UTI in developing and underdeveloped nations is also restraining the growth of the market.

Scope of the Report

A urinary tract infection (UTI) is an infection that affects part of the urinary tract. It is one of the most common bacterial infections, more common in women as compared to men. UTI is counted amongst one of the frequent causes of morbidity and mortality globally.

Drug
		Penicillin & Combinations
		Quinolones
		Cephalosporin
		Azoles & Amphotericin B
		Nitrofurans
		Others (Aminoglycoside Antibodies, Sulphonamides, Tetracycline etc.)

Indication
		Complicated UTI
		Uncomplicated UTI
		Others (Recurring Complicated UTI, Neurogenic Bladder Infection etc.)

Geography

North America
	US
	Canada
	Mexico

Europe
	Germany
	UK
	France
	Italy
	Spain
	Rest of Europe

Asia Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle East and Africa
	GCC
	South Africa
	Rest of Middle East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Complicated UTI is Expected to Show Lucrative Growth in the Indication Segment

The prevalence of uncomplicated UTI is significantly higher as compared to recurring complicated UTI; however, the prevalence of complicated UTI is expected to increase in the future, owing to increase in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones in their daily practice to treat complicated UTI cases. Cephalosporin is the second-most common drug in the complicated UTI segment. Overall, the prevalence of complicated UTI is set to increase during the forecast period, owing mainly to increasing bacterial resistance in UTI cases and the increase in recurrence rate for UTIs.

Urinary Tract Infection Therapeutics Market_Image 2

To understand key trends, Download Sample Report

North America Dominates the Market and is Expected to do Same in the Forecast Period

The region is experiencing a drastic increase in innovation related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was actually carrying an E. coli containing resistance to the last-resort antibiotic Colistin. The discovery of Colistin-resistant bacteria is worrisome, but that it was found in the urine sample put the discovery into a larger context. In addition to that, CDC, in collaboration with other organizations, has developed guidelines for the prevention of Catheter-associated UTIs and other types of healthcare-associated infections in the United States.

Urinary Tract Infection Therapeutics Market_Image 3

To understand geography trends, Download Sample Report

Competitive Landscape

The global Urinary Tract Infection Therapeuticsmarket is highly competitive and consists of a number of major players. Companies like AstraZeneca, Bayer AG, Cipla, Inc., GlaxoSmithKline PLC, Merlion Pharma, Novartis AG, Pfizer, among others, hold the substantial market share in the Urinary Tract Infection Therapeutics market.

Major Players

* Complete list of players covered available in the table of contents below

Urinary Tract Infection Therapeutics Market_Image 4

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
  2. 4.2.2 Launch of Combination Drugs
3. 4.3 Market Restraints
  1. 4.3.1 Adverse Effects Associated with the Use of Medication
  2. 4.3.2 Lack of Awareness in Developing and Underdeveloped Nations
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 Drug
  1. 5.1.1 Penicillin & Combinations
  2. 5.1.2 Quinolones
  3. 5.1.3 Cephalosporin
  4. 5.1.4 Azoles & Amphotericin B
  5. 5.1.5 Nitrofurans
  6. 5.1.6 Others (Aminoglycoside Antibodies, Sulphonamides, Tetracycline etc.)
2. 5.2 Indication
  1. 5.2.1 Complicated UTI
  2. 5.2.2 Uncomplicated UTI
  3. 5.2.3 Others (Recurring Complicated UTI, Neurogenic Bladder Infection etc.)
3. 5.3 Geography
  1. 5.3.1 North America
    1. 5.3.1.1 US
    2. 5.3.1.2 Canada
    3. 5.3.1.3 Mexico
  2. 5.3.2 Europe
    1. 5.3.2.1 Germany
    2. 5.3.2.2 UK
    3. 5.3.2.3 France
    4. 5.3.2.4 Italy
    5. 5.3.2.5 Spain
    6. 5.3.2.6 Rest of Europe
  3. 5.3.3 Asia Pacific
    1. 5.3.3.1 China
    2. 5.3.3.2 Japan
    3. 5.3.3.3 India
    4. 5.3.3.4 Australia
    5. 5.3.3.5 South Korea
    6. 5.3.3.6 Rest of Asia-Pacific
  4. 5.3.4 Middle East and Africa
    1. 5.3.4.1 GCC
    2. 5.3.4.2 South Africa
    3. 5.3.4.3 Rest of Middle East and Africa
  5. 5.3.5 South America
    1. 5.3.5.1 Brazil
    2. 5.3.5.2 Argentina
    3. 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 AstraZeneca
  2. 6.1.2 Bayer AG
  3. 6.1.3 Cipla, Inc.
  4. 6.1.4 GlaxoSmithKline PLC
  5. 6.1.5 Merlion Pharma
  6. 6.1.6 Novartis AG
  7. 6.1.7 Pfizer
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments